Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Trial Profile

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs Semaglutide (Primary) ; Liraglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms PIONEER 9
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 20 Dec 2017 Planned End Date changed from 6 Sep 2018 to 20 Aug 2018.
    • 20 Dec 2017 Planned primary completion date changed from 2 Aug 2018 to 26 Jan 2018.
    • 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top